A Solution To Assist Diagnostic Specialists In Spreading Innovation And Controlling Disease

A novel screening test is changing the way tuberculosis is detected and controlled, thanks in part to a custom shipping solution from American Aerogel.

In the United States, tuberculosis elimination efforts focus on prevention. Rather than test for the active infection, healthy populations are screened for latent TB, most commonly through the tuberculin skin test that requires two patient visits and subjective interpretation of results. A new cellular blood test from Oxford Immunotec offers a simpler and more reliable process—requiring a single blood draw and achieving exceptional accuracy.

The T-SPOT®.TB test is a revolutionary “one and done” diagnostic test for the diagnosis of both active and latent tuberculosis. Developed by Oxford Immunotec, it detects the immune response of T cells that are activated by the tuberculosis bacteria. The test is the only one of its kind that demonstrated sensitivity and specifi city—the ability to accurately identify positive and negative results—that exceeds 95 percent in clinical studies. No special lab equipment is required and results are available the next day.